The growing prevalence of metabolic disease, CKD, and ASCVD have prompted investigation into the role of GLP-1R agonists in mitigating cardiovascular and metabolic risks, particularly within the framework of Cardiovascular-Kidney-Metabolic (CKM) Syndrome, irrespective of diabetic status
Summary: The adoption of these technologies and the establishment of novel therapeutic interventions is difficult since there is a gap in terms of a complete understanding of the pathophysiological mechanisms at the cellular and molecular level and the lack of data in terms of the assessment of safety and bioavailability differences in the individuals patients
Our program fees will be reviewed at your consultation
If you are reading this because alcohol cravings have been difficult to manage on your own, CBHs South Florida clinical team is available at 844-503-0126
Patients with certain GLP1R variants, for example, may benefit from earlier escalation to dual-compound therapy, while others optimize on semaglutide monotherapy
This approach ensures patients have access to necessary treatments, even when their usual medication is in short supply
